BioCentury | Feb 17, 2014
Financial News

Lithera financial update

...and Domain Associates; new investor AKS Capital; and additional undisclosed investors participated in the close. Lithera Inc....
BioCentury | Nov 25, 2013
Company News

Lithera management update

Lithera Inc. , San Diego, Calif. Business: Ophthalmic, Endocrine/Metabolic Hired: Lincoln Krochmal as CMO, formerly president and CEO of Excaliard Pharmaceuticals Inc. , which Pfizer Inc. acquired WIR Staff Ophthalmic...
BioCentury | Oct 7, 2013
Clinical News

LIPO-202: Phase IIb data

...and a 2-point improvement in CPnS score from baseline to week 9 vs. placebo (p<0.05). Lithera...
...Patients received placebo or 0.4, 1 or 4 µg LIPO-202 once weekly for 8 weeks. Lithera...
...and said data for the 1 and 4 µg doses of LIPO-202 were not disclosed. Lithera...
BioCentury | Oct 1, 2013
Clinical News

Lithera reports Phase IIb data for LIPO-202

...Global Abdominal Profile Scale (P-GAPS) score and a 2-point improvement in Clinician Photo-numeric Scale (CPnS). Lithera...
BioCentury | Jul 29, 2013
Financial News

Lithera financial update

...Venture Investment and Andrea Holdings. Undisclosed investors also participated. Lithera raised $20.6 million last December. Lithera Inc....
BioCentury | Mar 18, 2013
Clinical News

LIPO-202: Phase II started

...for 8 weeks in about 500 healthy patients with subcutaneous fat in the periumbilical area. Lithera Inc....
BioCentury | Dec 24, 2012
Financial News

Lithera completes venture financing

...Raised: $20.6 million Investors: Rusnano; Domain Associates; Alta Partners; Amorepacific Ventures; Numoda Capital Innovations Note: Lithera...
BioCentury | Dec 20, 2012
Financial News

Lithera raises $20.6 million

...Numoda Capital Innovations. Lithera said the round may be increased to up to $35.6 million. Lithera's...
...salmeterol xinafoate , is in development to reduce abdominal bulging due to excess subcutaneous fat. Lithera...
BioCentury | Mar 28, 2011
Company News

Lithera management update

Lithera Inc. , San Diego, Calif. Business: Ophthalmic, Endocrine Hired: George Mahaffey as president, CEO and a director, formerly CEO of Peplin Inc. , which was acquired by Leo Pharma A/S ; he succeeds founder and CEO...
BioCentury | Nov 22, 2010
Clinical News

LIPO-102: Phase IIb data

...London, U.K.) markets Advair salmeterol/fluticasone propionate to treat chronic obstructive pulmonary disease (COPD) and asthma. Lithera Inc....
Items per page:
1 - 10 of 13
BioCentury | Feb 17, 2014
Financial News

Lithera financial update

...and Domain Associates; new investor AKS Capital; and additional undisclosed investors participated in the close. Lithera Inc....
BioCentury | Nov 25, 2013
Company News

Lithera management update

Lithera Inc. , San Diego, Calif. Business: Ophthalmic, Endocrine/Metabolic Hired: Lincoln Krochmal as CMO, formerly president and CEO of Excaliard Pharmaceuticals Inc. , which Pfizer Inc. acquired WIR Staff Ophthalmic...
BioCentury | Oct 7, 2013
Clinical News

LIPO-202: Phase IIb data

...and a 2-point improvement in CPnS score from baseline to week 9 vs. placebo (p<0.05). Lithera...
...Patients received placebo or 0.4, 1 or 4 µg LIPO-202 once weekly for 8 weeks. Lithera...
...and said data for the 1 and 4 µg doses of LIPO-202 were not disclosed. Lithera...
BioCentury | Oct 1, 2013
Clinical News

Lithera reports Phase IIb data for LIPO-202

...Global Abdominal Profile Scale (P-GAPS) score and a 2-point improvement in Clinician Photo-numeric Scale (CPnS). Lithera...
BioCentury | Jul 29, 2013
Financial News

Lithera financial update

...Venture Investment and Andrea Holdings. Undisclosed investors also participated. Lithera raised $20.6 million last December. Lithera Inc....
BioCentury | Mar 18, 2013
Clinical News

LIPO-202: Phase II started

...for 8 weeks in about 500 healthy patients with subcutaneous fat in the periumbilical area. Lithera Inc....
BioCentury | Dec 24, 2012
Financial News

Lithera completes venture financing

...Raised: $20.6 million Investors: Rusnano; Domain Associates; Alta Partners; Amorepacific Ventures; Numoda Capital Innovations Note: Lithera...
BioCentury | Dec 20, 2012
Financial News

Lithera raises $20.6 million

...Numoda Capital Innovations. Lithera said the round may be increased to up to $35.6 million. Lithera's...
...salmeterol xinafoate , is in development to reduce abdominal bulging due to excess subcutaneous fat. Lithera...
BioCentury | Mar 28, 2011
Company News

Lithera management update

Lithera Inc. , San Diego, Calif. Business: Ophthalmic, Endocrine Hired: George Mahaffey as president, CEO and a director, formerly CEO of Peplin Inc. , which was acquired by Leo Pharma A/S ; he succeeds founder and CEO...
BioCentury | Nov 22, 2010
Clinical News

LIPO-102: Phase IIb data

...London, U.K.) markets Advair salmeterol/fluticasone propionate to treat chronic obstructive pulmonary disease (COPD) and asthma. Lithera Inc....
Items per page:
1 - 10 of 13